If CDC Director Rochelle Walensky, MD, endorses the FDA’s decision, the recommendation can go into effect this week.
Children from 12 to 15 years old can receive a COVID-19 booster shot, according to updated recommendations by the US Food and Drug Administration (FDA). The ruling comes as the Omicron variant continues its rapid spread across America, accounting for 59% of COVID-19 infections as of Saturday, according to the Centers for Disease Control and Prevention (CDC). It also comes during a public debate about whether children should return to in-person learning at schools.
CDC Director Rochelle Walensky, MD, will review the FDA’s recommendation and if endorsed by that agency, the FDA recommendation could go into effect as soon as this week.
Booster doses, a third shot for Pfizer-BioNTech and Moderna recipients or a second shot for Janssen (Johnson & Johnson) recipients, were previously indicated for all persons 16 and older. Now, children 12-15 may be eligible for booster shots as well.
Additionally, the FDA lowered the wait time in between the second and third doses for Pfizer-BioNTech recipients, from 6 months to 5.
The Pfizer-BioNTech vaccine is the only approved COVID-19 vaccination for children 12-17 years old, so if the CDC agrees, children 12 and older can and should receive a third Pfizer-BioNTech dose 5 months after their second.
The Omicron variant has proved more effective at causing breakthrough infections among vaccinated individuals, which prompted federal health agencies to move quickly to approve booster doses as soon as they are proven safe and effective.
Children are less likely to experience severe or fatal COVID-19 disease, but becoming vaccinated may inhibit them from taking up valuable space in already overcrowded hospitals, and can prevent them from spreading the virus to immunocompromised individuals.
This article originally appeared in Contagion®.
Redefining Competency: A Comprehensive Framework for Infection Preventionists
December 19th 2024Explore APIC’s groundbreaking framework for defining and documenting infection preventionist competency. Christine Zirges, DNP, ACNS-BC, CIC, FAPIC, shares insights on advancing professional growth, improving patient safety, and navigating regulatory challenges.
Addressing Post-COVID Challenges: The Urgent Need for Enhanced Hospital Reporting Metrics
December 18th 2024Explore why CMS must expand COVID-19, influenza, and RSV reporting to include hospital-onset infections, health care worker cases, and ER trends, driving proactive prevention and patient safety.
Announcing the 2024 Infection Control Today Educator of the Year: Shahbaz Salehi, MD, MPH, MSHIA
December 17th 2024Shahbaz Salehi, MD, MPH, MSHIA, is the Infection Control Today 2024 Educator of the Year. He is celebrated for his leadership, mentorship, and transformative contributions to infection prevention education and patient safety.
Pula General Hospital Celebrates Clean Hospitals
December 16th 2024Learn how Pula General Hospital in Croatia championed infection prevention and environmental hygiene and celebrated Clean Hospitals Day to honor cleaning staff and promote advanced practices for exceptional patient care and safety.
Understanding NHSN's 2022 Rebaseline Data: Key Updates and Implications for HAI Reporting
December 13th 2024Discover how the NHSN 2022 Rebaseline initiative updates health care-associated infection metrics to align with modern health care trends, enabling improved infection prevention strategies and patient safety outcomes.